Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
An in vitro hepatitis C virus (HCV) replication system that is capable of producing viral particles in a culture medium More
A series of SynLeptin peptides, particularly, SynLeptin-2 shows remarkable anti-obesity activities which were verified in animal experiments using mice and rabbits. More
Transgenic mice for screening compounds with therapeutic potential against pain, hyper-thyroidism or obesity. These transgenic mice over-express DREAM, a transcriptional repressor More
Adrenomedullin peptides and antibodies, which would be useful in the development of a therapeutic or for diagnostics use More
Related Reports
Market Research Reports provided by reports.innovaro.com
Aug 2011 - 8 pages - $75
Aug 2011 - 7 pages - $75
Aug 2011 - 7 pages - $75
Aug 2011 - 7 pages - $75
Aug 2011 - 8 pages - $75
Nov 2011 - 8 pages - $75
Jan 2006 - 21 pages - $1,100
May 2011 - 3 pages - $100
Feb 2011 - 15 pages - $125
May 2010 - 8 pages - $395
Your selection
Browse By
- Industry sector
- Antibodies
- Antigens
- Biomarkers
- Cell lines
- Mouse models
- Reagents
- Vectors
- Therapeutic target
- Anorexia
- Anti-oxidant
- Appetite
- Bulimia nervosa
- Cachexia
- Cirrhosis
- Diabetes type I
- Diabetes type II
- Diabetic complications
- Fabry's disease
- Gallbladder disorder (other)
- Gallstones
- Gaucher's disease
- Hepatic protectors
- Hepatic protectors
- Hypercholesterolemia
- Hyperparathyroidism
- Hypertriglyceridemia
- Liver cancer
- Liver disorders (other)
- Metabolic disorder (other)
- Mineral supplement
- Obesity
- Weight loss
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2012 Innovaro Europe Ltd 
All rights reserved. Terms and Conditions | Contact us